The following are multiple choice questions (with answers) about medical knowledge.   **Question:** A 53-year-old man with recurrent pancreatic adenocarcinoma is enrolled in a clinical trial for a novel chemotherapeutic agent that his physician believes may be beneficial to his condition. The novel drug was previously tested in a small population and is now undergoing a larger phase 3 trial in preparation for FDA approval. A dose-response trial had the following results:  10 mg dose - 6/59 patients demonstrated improvement 20 mg dose - 19/49 patients demonstrated improvement 30 mg dose - 26/53 patients demonstrated improvement 40 mg dose - 46/51 patients demonstrated improvement  The same trial also had the following safety profile:  20 mg dose - 5/49 patients had a treatment related adverse event 40 mg dose - 11/51 patients had a treatment related adverse event 60 mg dose - 15/42 patients had a treatment related adverse event 80 mg dose - 23/47 patients had a treatment related adverse event 100 mg dose - 47/52 patients had a treatment related adverse event  Based on this study, which of the following represents the most likely therapeutic index for this novel chemotherapeutic agent?   (A) 0.375   (B) 0.5   (C) 2.5   (D) 2.67
['(D) 2.67 <> answer', 'The following are multiple choice questions (with answers) about medical knowledge. <> instruction', '(A) 0.375 \n (B) 0.5 \n (C) 2.5 \n (D) 2.67 <> possible answers', '  A 53-year-old man with recurrent pancreatic adenocarcinoma is enrolled in a clinical trial for a novel chemotherapeutic agent that his physician believes may be beneficial to his condition. The novel drug was previously tested in a small population and is now undergoing a larger phase 3 trial in preparation for FDA approval. A dose-response trial had the following results:\n\n10 mg dose - 6/59 patients demonstrated improvement\n20 mg dose - 19/49 patients demonstrated improvement\n30 mg dose - 26/53 patients demonstrated improvement\n40 mg dose - 46/51 patients demonstrated improvement\n\nThe same trial also had the following safety profile:\n\n20 mg dose - 5/49 patients had a treatment related adverse event\n40 mg dose - 11/51 patients had a treatment related adverse event\n60 mg dose - 15/42 patients had a treatment related adverse event\n80 mg dose - 23/47 patients had a treatment related adverse event\n100 mg dose - 47/52 patients had a treatment related adverse event\n\nBased on this study, which of the following represents the most likely therapeutic index for this novel chemotherapeutic agent? <> context@']